Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence.This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected. © 2013 Elsevier Ltd.

Esposito A, 1., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L., et al. (2014). Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. CANCER TREATMENT REVIEWS, 40(5), 648-655 [10.1016/j.ctrv.2013.10.003].

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

COLOMBO, NICOLETTA;
2014

Abstract

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence.This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected. © 2013 Elsevier Ltd.
Articolo in rivista - Review Essay
Breast cancer; Cell free DNA; Circulating nucleic acids; Colorectal cancer; Lung cancer; Ovarian cancer; Plasma/serum DNA; Prostate cancer; Carcinogenesis; Colorectal Neoplasms; DNA, Neoplasm; Disease Progression; Female; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Neoplasms; Neoplastic Cells, Circulating; Ovarian Neoplasms; Predictive Value of Tests; Prostatic Neoplasms; Research; Risk Assessment; Tumor Markers, Biological; Oncology; Radiology, Nuclear Medicine and Imaging
English
2014
40
5
648
655
none
Esposito A, 1., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L., et al. (2014). Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. CANCER TREATMENT REVIEWS, 40(5), 648-655 [10.1016/j.ctrv.2013.10.003].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/97355
Citazioni
  • Scopus 103
  • ???jsp.display-item.citation.isi??? 88
Social impact